Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Conmed (CNMD) Shares Outstanding (2016 - 2026)

Conmed filings provide 17 years of Shares Outstanding readings, the most recent being $31.3 million for Q1 2026.

  • On a quarterly basis, Shares Outstanding changed 0.0% to $31.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $31.3 million, a 0.0% change, with the full-year FY2025 number at $31.3 million, changed 0.0% from a year prior.
  • Shares Outstanding hit $31.3 million in Q1 2026 for Conmed, roughly flat from $31.3 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $31.3 million in Q2 2022 to a low of $31.3 million in Q1 2022.
  • Median Shares Outstanding over the past 5 years was $31.3 million (2022), compared with a mean of $31.3 million.
  • Biggest five-year swings in Shares Outstanding: grew 0.0% in 2022 and later fell 0.0% in 2023.
  • Conmed's Shares Outstanding stood at $31.3 million in 2022, then changed by 0.0% to $31.3 million in 2023, then changed by 0.0% to $31.3 million in 2024, then increased by 0.0% to $31.3 million in 2025, then dropped by 0.0% to $31.3 million in 2026.
  • The last three reported values for Shares Outstanding were $31.3 million (Q1 2026), $31.3 million (Q4 2025), and $31.3 million (Q3 2025) per Business Quant data.